Analysts Are Bullish on These Healthcare Stocks: Sol-Gel Technologies Ltd (SLGL), TG Therapeutics (TGTX)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sol-Gel Technologies Ltd (NASDAQ:SLGL), TG Therapeutics (NASDAQ:TGTX) and Coherus Biosciences (NASDAQ:CHRS) with bullish sentiments.

Sol-Gel Technologies Ltd (SLGL)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sol-Gel Technologies Ltd today and set a price target of $21. The company’s shares closed yesterday at $6.80, close to its 52-week low of $6.03.

Selvaraju noted:

“We have valued Sol-Gel based on a discounted cash flow (DCF)-based analysis. This yields a value of $102M for TWIN, assuming a 50% probability of success, and a $323M valuation for VERED, assuming a 60% probability of success.”

According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 6.8% and a 45.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Sol-Gel Technologies Ltd is a Moderate Buy with an average price target of $21.

See today’s analyst top recommended stocks >>

TG Therapeutics (TGTX)

H.C. Wainwright analyst Edward White maintained a Buy rating on TG Therapeutics today and set a price target of $21. The company’s shares closed yesterday at $5.15, close to its 52-week low of $5.10.

According to TipRanks.com, White is a 5-star analyst with an average return of 22.5% and a 50.0% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.

TG Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $23.

Coherus Biosciences (CHRS)

In a report released today, Jason Kolbert from H.C. Wainwright maintained a Buy rating on Coherus Biosciences, with a price target of $28. The company’s shares closed yesterday at $16.60.

Kolbert commented:

“We are thrilled to see that the European Commission (EC) has granted marketing authorization to UDENYCA (Sept. 25, 2018). The decision follows the positive recommendation from the Use (CHMP) this past summer (July 2018) in support of marketing authorization of UDENYCA. As a reminder, the committee then reviewed all the new immunogenicity data that were required for the U.S. re-submission too, so the EU approval adds a measure of confidence in support of our thinking U.S. approval happens later this year. How big is Europe? We estimate the EU market size at approximately one billion dollars, or one quarter the size of the U.S. UDENCYA is likely to be one of several pegfilgrastim biosimilars that will compete for share in Europe. Ultimately there may be as many as five pegfilgrastim biosimilars in Europe.”

According to TipRanks.com, Kolbert ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.1% and a 39.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Can-Fite BioPharma.

Currently, the analyst consensus on Coherus Biosciences is a Strong Buy with an average price target of $26, representing a 56.6% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $25 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts